Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors. Our unique platform technologies seek to harness the body’s immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies. Our product pipeline includes multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies. We are supported by a leading team of international cancer experts with extensive experience in developing new cancer therapies with many approved for sale and marketing for global markets. ASX: IMU
Looking for a particular Imugene Limited employee's phone or email?
Imugene Limited Questions
The Imugene Limited annual revenue was $71.9 million in 2026.
Leslie Chong is the Chief Executive Officer and Managing Director of Imugene Limited.
37 people are employed at Imugene Limited.
Imugene Limited is based in Sydney, New South Wales.
The NAICS codes for Imugene Limited are [541714, 541, 54, 5417, 54171].
The SIC codes for Imugene Limited are [87, 873].
Top Imugene Limited Employees
-
25
-
Nicholas Ede
Chief Technology Officer at Imugene Limited
Melbourne, VIC, AU21 -
Brad Glover
Chief Operating Officer at Imugene Limited
California, United States42 -
John Byon
Chief Medical Officer at Imugene Limited
San Francisco, CA, US21 -
Garrett Gincley
Vice President Technical Operations at Imugene Limited
Chapel Hill, NC, US31 -
Erik Poulsen
Vice President, Regulatory Affairs at Imugene Limited
California, United States33 -
Amanda Seiz
Vice President - Clinical Operations at Imugene Limited
St. Louis, MO, US45+ -
Ursula McCurry
Senior Vice President Clinical Operations at Imugene Limited
San Francisco, CA, US22
Related Companies
